Skip to content

Revvity RVTY Net Income

Net Income at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$1.66B+9.6%
Danaher logo
DanaherDHR
$1.03B+7.9%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
-$77.9M-189%
WAT
Waters CorporationWAT
-$72M-160%
Agilent Technologies logo
Agilent TechnologiesA
$339M+57.7%
Illumina logo
IlluminaILMN
$134M+2.3%

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revvity's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revvity's net income?
Revvity (RVTY) reported net income of $40.72M in Q1 2026.
How has Revvity's net income changed year-over-year?
Revvity's net income decreased by 3.6% year-over-year, from $42.24M to $40.72M.
What is the long-term trend for Revvity's net income?
Over 4 years (2021 to 2025), Revvity's net income has grown at a -28.9% compound annual growth rate (CAGR), from $943.16M to $241.2M.
What does net income mean?
The company's total bottom-line profit for the period.
How do you interpret net income?
An increase indicates higher profitability and potential for reinvestment or shareholder returns, while a decrease may signal operational challenges or margin compression.
How does net income compare across companies?
Standardized across all public companies; peers in life sciences typically show consistent growth in this metric.